Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Barclays has maintained its Equal-Weight rating for Blueprint Medicines (NASDAQ:BPMC) and increased its price target from $46.00 to $58.00. Blueprint Medicines' shares are currently trading up 4.09% over the last 24 hours, at $57.48 per share. A move to $58.00 would account for a 0.9% increase from the current share price.
October 27, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays has maintained its Equal-Weight rating for Blueprint Medicines and raised its price target, which could potentially lead to a positive impact on the company's stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. Barclays' decision to maintain its Equal-Weight rating and raise the price target for Blueprint Medicines indicates a positive outlook for the company, which could potentially lead to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100